| Age | Sex | BMI | G | Viral load (log) | F | Statut | DAA | Posology DAA | Duration (weeks) | Drug inter | Failure moment | VR NS3 | VR NS5A | Drugs resistance |
P1 | 42 | M | 18 | 1b | 5, 3 | F1 | Naïve | SOF + LED | 400 mg/jr + 90 mg/jr | 12 | No | M6 post- Treatment | none | Y93H L31M+ | LED |
P2 | 71 | F | 22 | 2L | 6, 31 | F4 | Naïve | SOF + RBV | 400 mg/jr + 800 mg/jr | 24 | No | M6 post- Treatment | none | Not amplifiable |
|
P3 | 60 | F | 21 | 1b | 6, 15 | F2 | Naïve | SOF + LED | 400 mg/jr + 90 mg/jr | 12 | No | M3 post- Treatment | none | 28L, 30T, 31V, 58S, 93H | LED, DACLA, VELPA, ELBAS OMBIT, PIBR↓ |
P4 | 82 | F | 28 | 1d | 6 | F2 | Naïve | SOF + LED | 400 mg/jr + 90 mg/jr | 12 | yes PPI | During treatment (M3) | none | 28V, 30A, 93N | LED, DACLA, ELBAS VELPA↓, PIBR↓ |
P5 | 56 | M | 28 | 1b | 6, 43 | F4 | Pre- Treated | SOF + LED | 400 mg/jr + 90 mg/jr | 12 | yes CCI (amlodipin) | Non- responders | (Q80k) | Q24k, L28T, R30S | LED, DACLA, ELBAS OMBIT, SIMEP, VELPA↓ |